History of Antibody Discovery
Since the 70s, scientists have progressively attempted to recreate
the human immune system’s most powerful disease fighting mechanism: first
through animal and chimeric hybridization and then humanized and recombinant
All of these methods had shortcomings through immune system rejection, toxicity, prohibitive costs, or limited antibody diversity.
Previous Limitations to Natural Human Antibody Discovery
1. Limited Lifespan of Antibody-Producing Cells Outside Body
2. Memory B Cell Rarity (0.001% of blood cells)
3. Signal among the noise - finding the most effective, relevant antibodies
Requires High Speed
Requires High Throughput
Requires High Resolution
How Our CellSpot Technology Works
CellSpot was designed to address previous limitations to native antibody discovery, chiefly the low frequency of useful antibodies against specific disease targets among millions of irrelevant antibodies; the short lifetime of human B-cells outside the body; and the challenge of efficiently cloning from single cells.
Trellis monoclonal antibodies (mAbs) have demonstrated efficacy and safety in their original, healthy donors.
Trellis infectious disease mAbs have demonstrated greater potency (in vitro and in vivo) than those from competitors.
1. Human Donors Naturally Produce Antigen-Binding B-Cells
2. CellSpot Identifies Memory B-Cells with Most Effective Antibodies
Multiple US Patents Issued
Capable of Discovering Rare, Broad-spectrum Immunities
4 therapies in preclinical/clinical manufacturing stages
via drastically miniaturized assays
Ability to identify extremely rare antibodies
via digital microscopy and custom software
Ability to screen millions of B-cells in weeks
via nanoparticle reagent technology
Ability to rapidly characterize antibody affinity and specificity
3. Target Antibody is Cloned and Therapies Generated
Target Memory B-Cell expressing most effective antibody
Single-cell cDNA Cloning